Denis, L.J.

cancer screening prostate cancer prostate study patient group interval mortality erspc european treatment sam 486 control interval cancers death control group result country control arm analysis contamination number effect level screening group table trial centre grade incidence biopsy european randomised study european randomized study prostate cancer mortality infusion center rotterdam screening interval difference schr öder fh randomised testing urology roobol disease detection antwerp reduction randomized nonattendance value follow-up ratio health interval cancer psa testing administration screening arm antigen psa use 4 years university polyamine journal cohort erasmus mc department netherland stage subject pca deaths society dose levels prostate cancers men randomised dose level outcome 270 mg /m prostate cancer screening